ROYAL OAK, Mich.--(BUSINESS WIRE)--Immunis.AI, a privately held immunogenomics company with a patented liquid biopsy platform, today announced that its President and Chief Executive Officer, Mark McDonough, will present at the BIO CEO & Investor Conference being held in New York City from February 10-11, 2020.
Date: Tuesday, February 11th
Time: 10:00 AM
Track: Diagnostics
Venue: Ziegfeld Room, New York Marriott Marquis, 1535 Broadway, New York, NY 10036
To schedule a meeting with Mark McDonough during the conference, please contact patrickthompson@ententeinc.com.
About Immunis.AI
Immunis.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology, for a truly individualized assessment. Our Intelligentia™ platform combines the power of the immune defense system, RNAseq technology and machine learning for the development of proprietary disease-specific algorithms. Our approach compares the differential gene expression patterns from two immune cells, using the patient as the control, normalizing and enhancing the signal of the underlying pathology. Intelligentia™ is a disruptive alternative, leveraging the immune system’s surveillance apparatus to overcome the limitations of cfDNA and CTC’s, enabling us to improve early stage disease detection, at the point of immune-escape, when there is the best opportunity for cure. For more information, please visit: immunis.ai
